The global pharma robots market worth is expected to rise at a rate of 15.2% per year to reach USD 683.4 Million by 2032.
supported by:
| Attributes | Details |
|---|---|
| Global Pharma Robots Market CAGR (2022 to 2032) | 13.8% |
| Global Pharma Robots Market Size (2022) | USD 188.6 Million |
| Global Pharma Robots Market Size (2032) | USD 683.4 Million |
| USA Pharma Robots Market CAGR (2022 to 2032) | 15.2% |
| Key Companies Covered | ABB Ltd.; Universal Robots; Kawasaki Heavy Industries Ltd.; Yaskawa Electric Corporation; FANUC America Corporation; Marchesini Group S.P.A; Seiko Epson Corporation; Denso Wave Incorporation; Jianjia Robots |
As a result of the 4th Industrial Revolution, there has been widespread adoption of automation, and lab automation is now widely used in all industries including the pharmaceutical sector. Furthermore, the need for higher precision and accuracy in the manufacturing of medicine is a major contributing reason to the expansion of the worldwide market for pharmaceutical robots.
Major issues related to drug development, such as cost savings and mistake reduction, are helped by the use of robots in pharmaceutical manufacturing. A robot-enabled solution can cut expenditures in a quality control lab by 25% to 45% for which market penetration has become easier for existing as well as new players of the pharma robots market.
Many National governments are also stressing the use of pharma robots in publicly funded pharmaceutical companies which is anticipated to further strengthen the overall market. Robots do lab work with reduced possibility of contamination and produce findings that are error-free. In addition to these, lab automation makes it feasible to do tasks like screening, plate replication, reformatting, and protein extraction easier.
Other than that, the unavailability of sufficient manpower to work in pharmaceutical manufacturing industries in developed economies is emerging as a significant driver for the adoption of pharma robots in these regions.
To reduce the export quantity from the Eastern nations USA is emphatically stressing the use of pharma robots in its domestic sector. However, the insufficiency of trained and expert personnel for operating pharma robotics in traditional pharmaceutical export countries such as India and China is lagging behind in the pharma robots market trends.
According to the manufacturer, new pharmaceutical robots can automate up to 80% of a pharmacy's oral solutions with precision for medicine and dosage, helping to save expenses and pharmaceutical mistakes. Such advantages have made the product indispensable for giant pharmaceutical companies making them the largest end-use vertical for the global pharma robots market.
Leading providers of pharmacy technology solutions are encouraging company expansion for improved patient outcomes. For instance, Parata Systems introduced Max 2, as a next-generation vial-filling robot, on October 10th, 2019. This robotic pharmacy system automates vial labeling, filling, and capping in an effort to improve efficiency and accommodate the demands of fast-paced pharmacies.
Integration of some advanced features by the key players has also increased the attractiveness of pharma robots in the smaller manufacturing units. For example, the recently developed Max 2 has various new improvements, including improved software with user-friendly navigation, color-coded LEDs that give visible cues to pharmacy group members, and vials that are replenished.
The Max 2 includes a verification camera that records the contents of each vial before capping, automatic drug cellular calibration for prompt and accurate
National Drug Code (NDC) updates, and a 2D barcode scanner that shortens the time required for manual NDC registration is another recent development that is poised to increase the usability of the product and create some further opportunities for the pharma robots market. Many new market participants are enthusiastically picking up these advantages to create a new client base in such a competitive market.
As per the Pharma Robots Market research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2017 to 2021, market value of the Pharma Robots Market increased at around 11.1% CAGR.
High revenue is predicted due to the demand for high-quality drugs, which in turn increases the dependence of pharma companies on robots and automatic equipment. The benefit that robotics provides are lesser area utilization, reduced production downtime, improved health and safety, superior waste management, and improved production output and product quality.
The deployment of Robotics is expected to increase in the upcoming years, owing to the rising pharmaceutical business and numerous benefits given by Robotic automation.
In December 2021, Universal Robots launched a virtual pharma event, where managers, experts, and other professionals in the pharmaceutical and medical technology industries learned about the various possibilities that robots provide. Universal Robots sees a lot of promise in the pharmaceutical industry and is looking to conduct more such events, which is already generating a lot of buzz in the market.
Pharma Robots have the potential to boost productivity and it has the ability to reintroduce manufacturing production jobs to both developed countries like USA and UK and developing countries like China and India. Traditional Robots like Articulated and SCARA robots will be mainly used for production and packaging purposes. This has escalated the demand of robots for use in pharmaceutical manufacturing.
The drivers affecting the demand for pharmaceutical robots during the production period are an increase in the investments and funding in the robotics segment, succeeding pharmaceutical industries, and increased conferences, and exhibitions, like Sao Paulo Expo, where companies demonstrate their robots to the potential users and most importantly increase in the participation of the domestic economies towards robotics and artificial intelligence.
The other drivers motivating companies to adopt robotics are cost reduction, improved quality and high production volume.
In the Pharmaceutical sector, the usage of robotics has been on a continuous surge. Since robots can perform their tasks 3-4 times faster than humans and can be used for a longer time period, the global workforce in many fields is being substituted by robots. These characteristics enable them to produce large quantities in a short period of time which was especially required during Covid-19.
To improve the sustainability of its operations, the pharmaceutical industry has had to reduce waste and pollutants while also conserving energy. Robots can undoubtedly contribute to these goals, as the motors, drives, and gearboxes that power them have been found to be up to 95% energy efficient.
Because of robots' increased efficiency and dependability, there are fewer rejected products and wasted materials, saving millions of dollars. Furthermore, because each robot is made up of disposable components, cleaning costs, as well as the amount of water and chemicals consumed, are reduced, lowering carbon footprints.
Nowadays, Collaborative Robots (Cobots) are also being used in the pharmaceutical industry to ensure the safety of the workers. At Copenhagen University Hospital, Cobots are being used to improve care quality. Instead of providing patient care, Cobots are being used in the hospital's laboratory.
Universal Robots' UR5 robots help lab personnel in getting off from monotonous and time-consuming tasks. They sort about 7-8 samples per minute and about 3,000 tubes per day. A surveillance system can help with this. The samples are then sorted by color and placed in the appropriate compartment by the robots.
Asia Pacific is projected to account for the highest growth opportunity, where the market in countries like Japan, China and South Korea are predicted to account for a CAGR of 16.1%, 14.5% and 10.2%, respectively. It is mainly due to growing need for automation in the pharmaceutical industry in the region.
Another aspect supporting this market's growth is the minimization of errors due to human intervention. Adoption of such a pharmaceutical robots system result in immediate cost reductions in human labour, lowering production costs and promoting market expansion.
In China, more than 40 businesses have joined the medical robot market. Nearly half of them raised financing totalling more than USD 58.9 Million in 2019. The robotics in the pharmaceutical industry in the country is booming, owing to government incentives, a rapidly ageing population, rising personal incomes, and rapid technological improvement.
As a result, top pharmaceutical corporations with large production facilities in these nations are projected to drive the regional market forward.
The United States is expected to have the highest market share of USD 203.6 Million by the end of 2032. This is mainly due to advancements in technology, increased investments in research and development, and the availability of skilled engineers and artificial intelligence experts.
Because of the substantial presence of global pharmaceutical businesses in the United States, as well as the high adoption of production automation in this region, the market in North America is expected to develop at a significant rate.
The market through Traditional Robots are forecasted to grow at the highest CAGR of over 14.5% during 2022 to 2032. Due to the rise in the acceptance in material handling, picking and packaging, and inspection, traditional robots accounted for the largest revenue share of almost 65%, in 2021.
High precision, cleanliness, and authentication standards are required in the pharmaceutical industry, thus compelling them to use traditional robots, which are cost-effective as compared to collaborative robots. The precision of traditional robots, like articulated robots in pharmaceutical applications, is leading to the surge in their demand.
They can have both protected sleeves and sealed joints. These are crucial requirements for cleanroom devices. Pick and place, dispensing, and scanning are all common applications.
In 2021, the picking and packing division generated the most revenue of almost 55%, and is expected to expand at the highest rate throughout the projected period. The strong demand for customized packaging and the benefits connected with it, like fast speed, efficient tracking, and optimal floor space usage, are primarily responsible for this increase. Moreover, picking and packaging are the primary uses of all traditional robotic technologies.
The recent innovation in the picking and packaging segment is the four-axis SCARA robot, which is a popular type of pick-and-place robot. Due to their high speed and accuracy, these robots are commonly used in pick-and-place applications. They are securely fastened and fixed with the arm positioned on the z-axis. SCARA robots can also perform tasks such as sorting, dispensing, inspecting, assembling, and inserting objects.
Players in the market are constantly developing improved analytical solutions as well as extending their product offerings. The providers of pharmaceutical robots are focused on alliances, technology collaborations, and product launch strategies.
Some of the recent developments of key Pharma Robots providers are as follows:
Similarly, recent developments related to companies’ pharmaceutical robots products have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2017 to 2021 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, U.K., France, Spain, Italy, Russia, China, Japan, South Korea, India, Australia, South Africa, Saudi Arabia, UAE and Israel. |
| Key Market Segments Covered | Product Type, Application, End-Use, Region |
| Key Companies Profiled |
ABB Ltd.; Universal Robots; Kawasaki Heavy Industries Ltd.; Yaskawa Electric Corporation; FANUC America Corporation; Marchesini Group S.P.A; Seiko Epson Corporation; Denso Wave Incorporation; Jianjia Robots |
| Pricing | Available upon Request |
The global Pharma Robots Market is worth more than USD 168.2 Million at present.
Value of Pharma Robots Market are projected to increase at a CAGR of around 13.8% during 2022 to 2032.
Value of Pharma Robots Market increased at a CAGR of around 11.1% during 2017 to 2021.
Increase in the research and development activities, high productivity ratio, reduction in the labor turnover, quality improvement, and increase in the participation of developing economies in the pharmaceutical sectors, are some of the key factors for the growth in the Pharma Robots Market.
The market for Pharma Robots Market in China is projected to expand at a CAGR of around 14.5% during 2022 to 2032.
While the market in South Korea is expected to grow at nearly 10.2%, the market in Japan is projected to register a CAGR of nearly 16.1% during 2022 to 2032.
Explore Similar Insights
Pharma Robots Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
